Skip to content

The Effectiveness of a Mobile Interactive Supervised Therapy (MIST) Intervention for Improving Adherence to HIV Medication

The Feasibility and Preliminary Efficacy of a Mobile Interactive Supervised Therapy (MIST) Intervention for Improving Medication Adherence of Patients With HIV Infection: a Pilot Randomised Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03794648
Enrollment
40
Registered
2019-01-07
Start date
2018-02-13
Completion date
2018-12-31
Last updated
2019-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV-infection/Aids

Keywords

mobile app, HIV-infections, medication adherence

Brief summary

A total of 40 HIV infected patients will be randomly assigned into intervention or control group. Participants in the intervention group will use an smart phone application for two months. Participants will receive reminder notifications and use the app to take and send videos of themselves taking the pill(s), uploaded videos will be centrally reviewed by a study nurse . Control group participants will receive standard care. Antiretroviral Therapy adherence will be measured by self-report, pill count, and smart bottle as well as the App. Participants' perceptions of app using experience will be recorded via face to face interview.

Interventions

BEHAVIORALMobile Interactive Supervised Therapy (MIST)

MIST system will send a reminder notification (via push or SMS) to participants 10 to 15 minutes before the scheduled time for taking their medication. Participants will then activate the recording function of the MIST app on their phone, and record themselves taking their medication.Participants will be asked to go through a series of steps for recording the video.

Sponsors

National University Hospital, Singapore
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 21 * HIV infection diagnosis confirmed by western blot * Taking a once daily regimen of HIV medications * Able to take pills orally * Willing and able to give informed consent

Exclusion criteria

* Inability to operate a smart phone * Active Tuberculosis infection requiring treatment during study (due to additional challenge posed to adherence that may confound the assessment of HIV adherence) * Substance use * Visual or hearing impairment * Cognitive impairment

Design outcomes

Primary

MeasureTime frameDescription
Change from one month percentage ART adherence at two months (by MEMScap)one-month follow-up and two-month follow-up visitsChange percentage ART adherence over the 2 month study period, as measured by MEMScaps, collected at the 1 and 2 month visits.

Secondary

MeasureTime frameDescription
Percentage ART adherence (self-reported)Baseline visit, one-month follow-up visit and two-month follow-up visits (end of study visit)Percentage self-reported adherence over a 21 day period (summation of the 7 days preceding each study visit) as measured by a standardised questionnaire at each study visit
Percentage ART adherence (by pill count)One-month follow-up visit, two-month follow-up visit(end of study visit)Percentage adherence over the 2 month study period, as measured by pill count, collected at month 1 and 2 follow-up visits
Variability in time (minutes) between prescribed pill time and actual dose takenOne-month follow-up visit, two-month follow-up visit(end of study visit)Variability in time (minutes) between prescribed pill time and actual dose taken, as measured by MEMScaps, collected at the 1 and 2 month visits.
Participants' perceptions on using MIST interventiontwo-month follow-up visit (end of the study visit)Participants' perception of MIST intervention , assessed at the 2 month visit by a sei-structured interview. The interview mainly addressed five areas namely: perception of overall MIST app use experience, perceived usefulness of each feature, strengths and weakness of MIST, interest in continued to use MIST for future and recommendations for further improvements.

Countries

Singapore

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026